Trials / Completed
CompletedNCT02013349
DESolve Post-Approval Study
POST-MARKET EVALUATION OF DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Elixir Medical Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the long-term safety and performance of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
Detailed description
DESolve is not currently approved for sale in the United States.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | coronary intervention |
Timeline
- Start date
- 2014-04-22
- Primary completion
- 2015-10-01
- Completion
- 2019-04-01
- First posted
- 2013-12-17
- Last updated
- 2020-04-08
Locations
7 sites across 3 countries: Germany, Italy, Jordan
Source: ClinicalTrials.gov record NCT02013349. Inclusion in this directory is not an endorsement.